Sumary of Novel CAR-T induces response prior to HSCT in younger patients with advanced AML:
- A novel chimeric antigen receptor T-cell therapy showed clinically relevant antitumor activity in nine of 11 younger patients with relapsed or refractory acute myeloid leukemia, according to early data from a phase 1/phase 2 study..
- Results of the trial — presented during the virtual ASCO Annual Meeting — may indicate a role for the CAR T-cell therapy as an effective bridging strategy before hematopoietic stem cell transplant, according to the researchers..
- Zhang said, adding that several preclinical studies have demonstrated the antitumor efficacy of targeting CLL1 in humanized models..
- Eight patients received CLL1-targeted CAR T cells, whereas three patients received a bispecific CAR that also targeted the CD33 protein..
- Patients received the dual-targeted CLL1/CD33 CAR T cells if they had lower expression of CLL1, Zhang told Healio..
- In each case, he added, the scientific team discussed the proper construct to use before proceeding to CAR T-cell therapy for AML..
- Patients received a lymphodepletion chemotherapy regimen of cyclophosphamide and fludarabine, followed by a single IV infusion of 0.3 × 106/kg to 1 × 106/kg CAR T cells..
- The three patients who received CLL1/CD33-directed CAR T cells had either grade 1 or grade 2 hepatoxicity that was not experienced by any patient who received CLL1-directed CAR T cells….